U.S. FDA panel backs Aerie’s glaucoma drug Rhopressa

(Reuters) – Aerie Pharmaceuticals Inc’s experimental glaucoma treatment should be approved, an advisory committee to the U.S. Food and Drug Administration said on Friday, after it found the benefits outweigh the risks.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply